DA Davidson Has Lowered Expectations for Cellebrite DI (NASDAQ:CLBT) Stock Price

Key Points

• DA Davidson cut Cellebrite DI’s price target from $22 to $15 while maintaining a Buy rating, implying roughly 37% upside from the prior close. Needham also lowered its target to $12.50, though the analyst consensus remains “Moderate Buy” with an average target of $19.90.
• Cellebrite’s quarterly EPS of $0.11 exceeded expectations, but revenue slightly missed estimates and the company’s reduced revenue and ARR outlook raised concerns about slowing growth. Shares were trading at $10.94, near their one-year low.
• Insiders have been selling shares: the CFO and CEO sold a combined roughly 181,000 shares in recent transactions, while insiders sold nearly 298,000 shares worth about $4.6 million over the last quarter.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its target price reduced by stock analysts at DA Davidson from $22.00 to $15.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. DA Davidson's price target would suggest a potential upside of 37.17% from the stock's previous close.

A number of other research analysts also recently issued reports on the stock. Needham & Company LLC reduced their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a research report on Friday. Weiss Ratings upgraded shares of Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $19.90.

Cellebrite DI Price Performance

Shares of CLBT stock traded up $0.14 on Friday, hitting $10.94. 1,418,095 shares of the stock traded hands, compared to its average volume of 2,095,445. The company has a market capitalization of $2.73 billion, a PE ratio of 38.95, a PEG ratio of 1.89 and a beta of 1.18. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98. The company's fifty day moving average is $14.52 and its 200 day moving average is $14.05.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.06. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.The firm had revenue of $131.14 million for the quarter, compared to analysts' expectations of $131.87 million. As a group, equities research analysts expect that Cellebrite DI will post 0.41 EPS for the current year.

Insider Buying and Selling

In related news, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the sale, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas E. Hogan sold 139,713 shares of the business's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the transaction, the chief executive officer directly owned 790,548 shares of the company's stock, valued at $12,166,533.72. The trade was a 15.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 297,934 shares of company stock valued at $4,631,972 in the last quarter. Company insiders own 5.70% of the company's stock.

Institutional Trading of Cellebrite DI

Large investors have recently added to or reduced their stakes in the business. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its stake in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock worth $34,000 after purchasing an additional 850 shares in the last quarter. CWM LLC raised its stake in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $44,000 after purchasing an additional 889 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock worth $597,000 after purchasing an additional 970 shares during the period. Alamea Verwaltungs GmbH grew its position in Cellebrite DI by 4.3% in the 4th quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company's stock valued at $444,000 after buying an additional 1,018 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in Cellebrite DI by 45.1% during the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company's stock valued at $72,000 after buying an additional 1,238 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.

More Cellebrite DI News

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported adjusted second-quarter EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat. Subscription revenue continued to grow, and management raised its adjusted EBITDA target. Cellebrite earnings and outlook announcement
• Positive Sentiment: Needham lowered its price target from $15.00 to $12.50 but maintained a Buy rating, implying potential upside from the current trading level. D.A. Davidson also retained its Buy rating. Needham analyst action
• Positive Sentiment: Unusually heavy call-option activity—nearly 20,000 contracts versus average volume of about 586—indicated that some traders were positioning for a rebound, although this is speculative and not a fundamental improvement.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, appointing Shiven Ramji to succeed Thomas E. Hogan. The change could support a strategic reset, but it also introduces uncertainty during a period of lowered forecasts. CEO transition announcement
• Negative Sentiment: The key reason for the selloff was the reduced outlook. Third-quarter revenue guidance of $145 million to $148 million was below the $150.3 million consensus, while full-year revenue guidance of $555 million to $561 million trailed the $568.1 million estimate. Cellebrite also lowered its full-year ARR forecast, signaling slower near-term growth. Cellebrite outlook report
• Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate. Some data providers also characterized EPS of $0.11 as below a $0.12 consensus, reinforcing concerns that the earnings beat was less important than the revenue and ARR shortfalls.
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and whether prior projections and disclosures were accurate. These are allegations, not established findings, but they add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his position by about 15%. The sale may be unrelated to business conditions, but its timing can weigh on investor sentiment. SEC insider sale filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source